BioCryst Pharma (BCRX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec18

BioCryst Pharmaceuticals Receives FDA Approval for Orladeyo Granules

04:38

Dec16

BioCryst's Chief Legal Officer Disposed of Company Common Stock

21:14

Dec12

Wedbush Analyst Maintains Buy Rating on BioCryst with $21 Price Target

13:38

Dec3

BioCryst Pharmaceuticals Plans to Merge with Astria Therapeutics

12:00

Nov12

BioCryst Pharmaceuticals to Acquire Astria Therapeutics for $8.55 per Share and 0.59 Shares

13:03

Nov8

HC Wainwright Raises BioCryst Pharmaceuticals' EPS Forecast for FY2025

14:20

Schedules & Filings

Schedules

Filings

Nov3

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 159.4 M, Net Income 12.9 M, EPS 0.06

Aug4

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 163.35 M, Net Income 5.085 M, EPS 0.02

May5

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 145.53 M, Net Income 32 K, EPS 0.0001

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change